Iga Nephropathy Igan Market

DelveInsight's "IgA Nephropathy (IgAN) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the IgA Nephropathy (IgAN), historical and forecasted epidemiology as well as the IgA Nephropathy (IgAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The IgA Nephropathy (IgAN) market report provides current treatment practices, emerging drugs, IgA Nephropathy (IgAN) market share of the individual therapies, current and forecasted IgA Nephropathy (IgAN) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current IgA Nephropathy (IgAN) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the IgA Nephropathy (IgAN) market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

IgA Nephropathy (IgAN) Disease Understanding and Treatment Algorithm

The DelveInsight’s IgA Nephropathy (IgAN) market report gives a thorough understanding of the IgA Nephropathy (IgAN) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

 

IgA Nephropathy (IgAN) Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for IgA Nephropathy (IgAN).

 

IgA Nephropathy (IgAN) Treatment

It covers the details of conventional and current medical therapies available in the IgA Nephropathy (IgAN) market for the treatment of the condition. It also provides IgA Nephropathy (IgAN) treatment algorithms and guidelines in the United States, Europe, and Japan.

IgA Nephropathy (IgAN) Epidemiology 

The IgA Nephropathy (IgAN) epidemiology section provides insights about the historical and current IgA Nephropathy (IgAN) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the IgA Nephropathy (IgAN) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted IgA Nephropathy (IgAN) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

Country Wise- IgA Nephropathy (IgAN) Epidemiology

The epidemiology segment also provides the IgA Nephropathy (IgAN) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

IgA Nephropathy (IgAN) Drug Chapters

The drug chapter segment of the IgA Nephropathy (IgAN) report encloses the detailed analysis of IgA Nephropathy (IgAN) marketed drugs and late-stage (Phase-III and Phase-II) IgA Nephropathy (IgAN) pipeline drugs. It also helps to understand the IgA Nephropathy (IgAN) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

IgA Nephropathy (IgAN) Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for IgA Nephropathy (IgAN) treatment.

 

IgA Nephropathy (IgAN) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for IgA Nephropathy (IgAN) treatment.

IgA Nephropathy (IgAN) Market Outlook

The IgA Nephropathy (IgAN) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted IgA Nephropathy (IgAN) market trends by analyzing the impact of current IgA Nephropathy (IgAN) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of IgA Nephropathy (IgAN) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated IgA Nephropathy (IgAN) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the IgA Nephropathy (IgAN) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the IgA Nephropathy (IgAN) market in 7MM.

 

The United States Market Outlook

This section provides the total IgA Nephropathy (IgAN) market size and market size by therapies in the United States.

 

EU-5 Countries: Market Outlook

The total IgA Nephropathy (IgAN) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan Market Outlook

The total IgA Nephropathy (IgAN) market size and market size by therapies in Japan is also mentioned.

IgA Nephropathy (IgAN) Drugs Uptake

This section focuses on the rate of uptake of the potential IgA Nephropathy (IgAN) drugs recently launched in the IgA Nephropathy (IgAN) market or expected to get launched in the market during the study period 2019-2032. The analysis covers IgA Nephropathy (IgAN) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

IgA Nephropathy (IgAN) Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of IgA Nephropathy (IgAN) market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

IgA Nephropathy (IgAN) Pipeline Development Activities

The IgA Nephropathy (IgAN) report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses IgA Nephropathy (IgAN) key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The IgA Nephropathy (IgAN) report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for IgA Nephropathy (IgAN) emerging therapies.

Reimbursement Scenario in IgA Nephropathy (IgAN)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current IgA Nephropathy (IgAN) market trends, we take KOLs and SMEs ' opinion working in the IgA Nephropathy (IgAN) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or IgA Nephropathy (IgAN) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the IgA Nephropathy (IgAN) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of IgA Nephropathy (IgAN), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the IgA Nephropathy (IgAN) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for IgA Nephropathy (IgAN) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the IgA Nephropathy (IgAN) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global IgA Nephropathy (IgAN) market

Report Highlights

  • In the coming years, the IgA Nephropathy (IgAN) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy (IgAN) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for IgA Nephropathy (IgAN). The launch of emerging therapies will significantly impact the IgA Nephropathy (IgAN) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for IgA Nephropathy (IgAN)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

IgA Nephropathy (IgAN) Report Insights

  • IgA Nephropathy (IgAN) Patient Population
  • Therapeutic Approaches
  • IgA Nephropathy (IgAN) Pipeline Analysis
  • IgA Nephropathy (IgAN) Market Size and Trends
  • IgA Nephropathy (IgAN) Market Opportunities
  • Impact of upcoming IgA Nephropathy (IgAN) Therapies

IgA Nephropathy (IgAN) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • IgA Nephropathy (IgAN) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

IgA Nephropathy (IgAN) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • IgA Nephropathy (IgAN) Pipeline Product Profiles
  • IgA Nephropathy (IgAN) Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the IgA Nephropathy (IgAN) drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the IgA Nephropathy (IgAN) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest IgA Nephropathy (IgAN) market size during the forecast period (2019-2032)?
  • At what CAGR, the IgA Nephropathy (IgAN) market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the IgA Nephropathy (IgAN) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the IgA Nephropathy (IgAN) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the IgA Nephropathy (IgAN)?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical IgA Nephropathy (IgAN) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of IgA Nephropathy (IgAN) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to IgA Nephropathy (IgAN)?
  • Out of all 7MM countries, which country would have the highest prevalent population of IgA Nephropathy (IgAN) during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the IgA Nephropathy (IgAN) treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of IgA Nephropathy (IgAN) in the USA, Europe, and Japan?
  • What are the IgA Nephropathy (IgAN) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of IgA Nephropathy (IgAN)?
  • How many therapies are in-development by each company for IgA Nephropathy (IgAN) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for IgA Nephropathy (IgAN) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the IgA Nephropathy (IgAN) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for IgA Nephropathy (IgAN) and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for IgA Nephropathy (IgAN)?
  • What are the global historical and forecasted market of IgA Nephropathy (IgAN)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the IgA Nephropathy (IgAN) market
  • To understand the future market competition in the IgA Nephropathy (IgAN) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for IgA Nephropathy (IgAN) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for IgA Nephropathy (IgAN) market
  • To understand the future market competition in the IgA Nephropathy (IgAN) market

1. Key Insights

2. Executive Summary of IgA Nephropathy (IgAN)

3. Competitive Intelligence Analysis for IgA Nephropathy (IgAN)

4. IgA Nephropathy (IgAN): Market Overview at a Glance

4.1. IgA Nephropathy (IgAN) Total Market Share (%) Distribution in 2019

4.2. IgA Nephropathy (IgAN) Total Market Share (%) Distribution in 2032

5. IgA Nephropathy (IgAN): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. IgA Nephropathy (IgAN) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. IgA Nephropathy (IgAN) Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. IgA Nephropathy (IgAN) Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. IgA Nephropathy (IgAN) Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. IgA Nephropathy (IgAN) Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. IgA Nephropathy (IgAN) Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. IgA Nephropathy (IgAN) Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. IgA Nephropathy (IgAN) Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. IgA Nephropathy (IgAN) Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. IgA Nephropathy (IgAN) Treatment and Management

8.2. IgA Nephropathy (IgAN) Treatment Algorithm

9. IgA Nephropathy (IgAN) Unmet Needs

10. Key Endpoints of IgA Nephropathy (IgAN) Treatment

11. IgA Nephropathy (IgAN) Marketed Products

11.1. List of IgA Nephropathy (IgAN) Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. IgA Nephropathy (IgAN) Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. IgA Nephropathy (IgAN): Seven Major Market Analysis

13.1. Key Findings

13.2. IgA Nephropathy (IgAN) Market Size in 7MM

13.3. IgA Nephropathy (IgAN) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. IgA Nephropathy (IgAN) Total Market Size in the United States

15.1.2. IgA Nephropathy (IgAN) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. IgA Nephropathy (IgAN) Total Market Size in Germany

15.3.2. IgA Nephropathy (IgAN) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. IgA Nephropathy (IgAN) Total Market Size in France

15.4.2. IgA Nephropathy (IgAN) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. IgA Nephropathy (IgAN) Total Market Size in Italy

15.5.2. IgA Nephropathy (IgAN) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. IgA Nephropathy (IgAN) Total Market Size in Spain

15.6.2. IgA Nephropathy (IgAN) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. IgA Nephropathy (IgAN) Total Market Size in the United Kingdom

15.7.2. IgA Nephropathy (IgAN) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. IgA Nephropathy (IgAN) Total Market Size in Japan

15.8.3. IgA Nephropathy (IgAN) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of IgA Nephropathy (IgAN)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM IgA Nephropathy (IgAN) Epidemiology (2019-2032)

Table 2: 7MM IgA Nephropathy (IgAN) Diagnosed and Treatable Cases (2019-2032)

Table 3: IgA Nephropathy (IgAN) Epidemiology in the United States (2019-2032)

Table 4: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: IgA Nephropathy (IgAN) Epidemiology in Germany (2019-2032)

Table 6: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: IgA Nephropathy (IgAN) Epidemiology in France (2019-2032)

Table 8: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in France (2019-2032)

Table 9: IgA Nephropathy (IgAN) Epidemiology in Italy (2019-2032)

Table 10: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: IgA Nephropathy (IgAN) Epidemiology in Spain (2019-2032)

Table 12: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: IgA Nephropathy (IgAN) Epidemiology in the UK (2019-2032)

Table 14: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: IgA Nephropathy (IgAN) Epidemiology in Japan (2019-2032)

Table 16: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM IgA Nephropathy (IgAN) Epidemiology (2019-2032)

Figure 2: 7MM IgA Nephropathy (IgAN) Diagnosed and Treatable Cases (2019-2032)

Figure 3: IgA Nephropathy (IgAN) Epidemiology in the United States (2019-2032)

Figure 4: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: IgA Nephropathy (IgAN) Epidemiology in Germany (2019-2032)

Figure 6: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: IgA Nephropathy (IgAN) Epidemiology in France (2019-2032)

Figure 8: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: IgA Nephropathy (IgAN) Epidemiology in Italy (2019-2032)

Figure 10: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: IgA Nephropathy (IgAN) Epidemiology in Spain (2019-2032)

Figure 12: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: IgA Nephropathy (IgAN) Epidemiology in the UK (2019-2032)

Figure 14: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: IgA Nephropathy (IgAN) Epidemiology in Japan (2019-2032)

Figure 16: IgA Nephropathy (IgAN) Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

Calliditas Therapeutics AB
Travere Therapeutics, Inc.
Omeros
Novartis Pharmaceuticals
Chinook Therapeutics, Inc.
Vera Therapeutics, Inc.

 

Forward to Friend

Need A Quote